Enanta Pharmaceuticals | ENTA - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 43.29B 3.9B 2025-12
Amgen USD 24.96B 534M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Immunic USD 30.62M 539K 2025-12
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 468.87M 51.66M 2025-12
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
Merck USD 26.94B 1.38B 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novavax USD 459.95M 30.08M 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03